Clin2
NCT07417124Possibly a fitRecruiting

Study of SNS851 for people with high liver fat

Metabolic Disease

Part of Hormones & metabolism clinical trials.

This study tests a new medicine called SNS851 in healthy volunteers to see if it is safe and tolerable. It may help people with high liver fat, though it is not yet known if it works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
52 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • Be between 18 and 55 years old (or up to 60 in some parts of the study)
  • Have a body mass index (BMI) between 18 and 32
  • Have higher than normal liver fat levels
  • Be generally healthy with no major health conditions
  • Not smoke or use nicotine products
  • Avoid caffeine and certain foods/drinks during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07214870Recruiting· Phase 1
A study of a new medicine for liver disease in adults with extra body weight and liver fat

This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.

Montreal, Quebec
NCT06891365Recruiting· Phase 1
Multiple doses of a new drug for fatty liver disease

This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.

Harrow
NCT07587710Not yet recruiting· Phase 1
Study of NNC0487-0111 in people with liver disease

This research study tests how a new medicine (NNC0487-0111) moves through your body and how well you tolerate it. The study compares people with healthy livers to people with reduced liver function to understand if liver disease affects how the medicine works.

Bratislava
NCT07308548Recruiting· Phase 2
Testing HP515 for fatty liver disease (NASH/MASH)

This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.

Beijing, Beijing Municipality
NCT03468556Not yet recruiting· Phase 2
Drug trial for non-alcoholic fatty liver inflammation (NASH)

This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.

NCT07198386Recruiting· Phase 2
Study of CS060380 tablets for NASH (fatty liver disease)

This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.

Fuzhou, Fujian

Hear when a new Metabolic Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.